390 related articles for article (PubMed ID: 10211539)
21. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
22. Effect of Maalox on the oral absorption of sparfloxacin.
Johnson RD; Dorr MB; Talbot GH; Caille G
Clin Ther; 1998; 20(6):1149-58. PubMed ID: 9916608
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Awni WM; Hussein Z; Cavanaugh JH; Granneman GR; Dubé LM
Clin Pharmacokinet; 1995; 29 Suppl 2():92-7. PubMed ID: 8620677
[TBL] [Abstract][Full Text] [Related]
24. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin.
Di Cicco RA; Miller AK; Patterson S; Freed MI
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1516-21. PubMed ID: 11185675
[TBL] [Abstract][Full Text] [Related]
25. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers.
Ding R; Tayrouz Y; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
Clin Pharmacol Ther; 2004 Jul; 76(1):73-84. PubMed ID: 15229466
[TBL] [Abstract][Full Text] [Related]
26. Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs.
Novotny MJ; Shaw DH
Can J Vet Res; 1991 Apr; 55(2):113-6. PubMed ID: 1884291
[TBL] [Abstract][Full Text] [Related]
27. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
[TBL] [Abstract][Full Text] [Related]
28. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Arold G; Donath F; Maurer A; Diefenbach K; Bauer S; Henneicke-von Zepelin HH; Friede M; Roots I
Planta Med; 2005 Apr; 71(4):331-7. PubMed ID: 15856409
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
30. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
[TBL] [Abstract][Full Text] [Related]
31. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers.
Tarral A; Francheteau P; Guerret M
Pharmacotherapy; 1997; 17(4):791-5. PubMed ID: 9250559
[TBL] [Abstract][Full Text] [Related]
32. The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.
Kamberi M; Nakashima H; Ogawa K; Oda N; Nakano S
Br J Clin Pharmacol; 2000 Feb; 49(2):98-103. PubMed ID: 10671902
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
34. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
35. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
Verstuyft C; Strabach S; El-Morabet H; Kerb R; Brinkmann U; Dubert L; Jaillon P; Funck-Brentano C; Trugnan G; Becquemont L
Clin Pharmacol Ther; 2003 Jan; 73(1):51-60. PubMed ID: 12545143
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40.
Tayrouz Y; Ding R; Burhenne J; Riedel KD; Weiss J; Hoppe-Tichy T; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2003 May; 73(5):397-405. PubMed ID: 12732840
[TBL] [Abstract][Full Text] [Related]
37. Effect of troglitazone on steady-state pharmacokinetics of digoxin.
Loi CM; Knowlton PW; Stern R; Randinitis EJ; Vassos AB; Koup JR; Sedman AJ
J Clin Pharmacol; 1998 Feb; 38(2):178-83. PubMed ID: 9549650
[TBL] [Abstract][Full Text] [Related]
38. Cimetidine does not alter sparfloxacin pharmacokinetics.
Gries JM; Honorato J; Taburet AM; Alvarez MP; Sadaba B; Azanza JR; Singlas E
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):585-7. PubMed ID: 8688981
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole does not affect the steady-state pharmacokinetics of digoxin.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):45-50. PubMed ID: 14616413
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
Zix JA; Geerdes-Fenge HF; Rau M; Vöckler J; Borner K; Koeppe P; Lode H
Antimicrob Agents Chemother; 1997 Aug; 41(8):1668-72. PubMed ID: 9257738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
